SCHEMBL3665701

SCHEMBL3665701

CCOc1ccc2cc(C(=O)NCCOc3ccc(C(=O)Nc4ccccc4N)cc3)oc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 11/20 0.63
HDAC2 Q92769 4/20 0.57
SMN1; SMN2 Q16637 2/20 0.55
HPGD P15428 1/20 0.55
TSHR P16473 1/20 0.55
HDAC3 O15379 5/20 0.48
KDM1A O60341 1/20 0.48
HDAC4 P56524 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3663481 0.94 HDAC2 (0.56) HDAC1HDAC2SMN1; SMN2HPGDTSHR
SCHEMBL3663432 0.92 HDAC1 (0.60) HDAC1HDAC2SMN1; SMN2HPGDTSHR
SCHEMBL3664762 0.92 HDAC1 (0.60) HDAC1HDAC2SMN1; SMN2HPGDTSHR
SCHEMBL3661503 0.91 HDAC1 (0.61) HDAC1HDAC2SMN1; SMN2HPGDTSHR
SCHEMBL3660004 0.90 HDAC1 (0.59) HDAC1HDAC2SMN1; SMN2HPGDTSHR
SCHEMBL3665620 0.90 HDAC2 (0.58) HDAC1HDAC2SMN1; SMN2HPGDTSHR
SCHEMBL3659009 0.90 HDAC2 (0.71) HDAC1HDAC2SMN1; SMN2HPGDTSHR
SCHEMBL3664653 0.89 HDAC1 (0.62) HDAC1HDAC2SMN1; SMN2HPGDTSHR
SCHEMBL3663929 0.89 HDAC1 (0.59) HDAC1HDAC2SMN1; SMN2HPGDTSHR
SCHEMBL3664753 0.89 HDAC1 (0.57) HDAC1HDAC2SMN1; SMN2HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292320-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS GILEAD COLORADO, INC. (US) 2010-11-18 US claimed
EP-2220066-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS Gilead Colorado, Inc. (US) 2010-08-25 EP claimed
WO-2009079391-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS GILEAD COLORADO, INC. (US) 2009-06-25 WO claimed
US-20100292320-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS GILEAD COLORADO, INC. (US) 2010-11-18 US disclosed
EP-2220066-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS Gilead Colorado, Inc. (US) 2010-08-25 EP disclosed
WO-2009079391-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS GILEAD COLORADO, INC. (US) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292320-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC7, HDAC5 HDAC1 1/4885HDAC2 4/4885SMN1; SMN2 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.